AuthorisedTherapeutic confirmatory (Phase III)Interventional

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

The DESIRE MS study is a research trial for people with multiple sclerosis (MS). It's comparing a new strategy that involves stepping down or changing MS treatments over time, against the current way of using anti-CD20 medications regularly. The main goal is to find out if the 'de-escalation' approach is just as effective at keeping MS quiet, meaning no new symptoms or changes on brain scans over three years. Researchers will also look at how these different treatment approaches affect relapses, disability, brain health, and overall quality of life. This trial aims to help doctors understand the best way to manage MS long-term for patients in the UK and beyond.

At a glance

Status

Authorised

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Centre Hospitalier Universitaire De Montpellier

Enrolment target

250

Start

28 Apr 2025

Multiple sclerosis

What is this study about?

This study is called DESIRE MS, and it's looking at treatments for multiple sclerosis, or MS. MS is a condition that affects your brain and spinal cord, and it can cause a range of symptoms. Doctors usually prescribe medicines to help manage the condition and prevent it from getting worse.

In this study, researchers want to see if changing the way certain MS medications are given can still be effective. Specifically, they are comparing a strategy of reducing or stopping some treatments over time (we call this 'de-escalation') with the usual approach of continuing a specific type of medication called anti-CD20 treatments. The main question they want to answer is: Is this 'de-escalation' approach just as good at keeping MS under control for three years?

Keeping MS 'under control' means that you don't experience any new MS symptoms (like a relapse) and your brain scans don't show any new or growing areas of inflammation. By understanding if a less intensive treatment strategy works well, this study could help doctors tailor treatments more effectively for people with MS in the future, potentially reducing side effects or the burden of long-term medication.

Key takeaways

Compares two ways of managing MS treatment over 3 years.
Aims to see if a less intense treatment approach is just as effective.
Looks at MS symptoms, brain scan changes, and overall well-being.
For adults aged 18 and over with relapsing-remitting MS.
Could help find better long-term treatment strategies for MS patients.

Who may be eligible?

To be considered for this study, you need to be an adult, 18 years old or older. There is no upper age limit for taking part. Both men and women are welcome to participate.

The study is specifically for individuals who have relapsing-remitting multiple sclerosis (RRMS), which is the most common form of MS. The researchers will be looking at your medical history and current MS status to make sure the study is a good fit for you.

Because this study is comparing existing treatments, you would likely already be diagnosed with MS and potentially already on a treatment plan. The doctors involved in the study will explain all the specific medical criteria to you in more detail if you are interested.

Quick self-check

Am I 18 years old or older?
Do I have a diagnosis of relapsing-remitting multiple sclerosis?
Am I able to commit to regular hospital visits and scans for 3 years?
Am I comfortable with the idea of potentially changing my MS treatment plan?

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you decide to take part in this study, you would be assigned to one of the treatment approaches being compared – either continuing with anti-CD20 maintenance treatment or following a de-escalation strategy. You would have regular appointments with the study team, which would involve check-ups, physical examinations, and blood tests. You would also have brain MRI scans at specific times over the three-year study period to monitor for any changes. The study lasts for a total of 36 months (3 years) and involves careful monitoring of your health, any MS symptoms you experience, and how you feel generally. All study medications would be provided.

Potential risks and benefits

Taking part in a clinical study can offer potential benefits, such as close monitoring of your MS and access to the latest treatment approaches. However, there are also potential risks, including side effects from the medications, which will be fully explained to you. The 'de-escalation' strategy might involve a different set of risks compared to continuous treatment. It's important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

—
France

Common questions

What is relapsing-remitting MS?

It's a type of MS where you have periods of new or worsening symptoms (relapses) followed by periods where symptoms improve or disappear (remission).

What does 'de-escalation' mean in this study?

It means gradually reducing or changing your MS treatment over time, rather than staying on the same medication continuously.

What are anti-CD20 treatments?

These are specific types of medications used for MS that target certain immune cells called B-cells to reduce inflammation.

What is a brain MRI scan?

It's a special type of scan that uses magnets and radio waves to create detailed pictures of your brain, allowing doctors to see any changes related to MS.

How long will the study last if I join?

The study will last for a total of 36 months, which is 3 years.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.